title: Amphotericin B deoxycholate for candidiasis in intensive care unit patients revisited: medical, ethical, and financial implications.
authors.forename: Didier
authors.initials: D
authors.lastname: Dreyfuss
authors.forename: Jean-Damien
authors.initials: JD
authors.lastname: Ricard
authors.forename: Stéphane
authors.initials: S
authors.lastname: Gaudry
mesh_terms: D000666:Amphotericin B / Q000009:adverse effects / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy*; D003404:Creatinine / Q000097:blood; D016638:Critical Illness; D003428:Cross Infection / Q000188:drug therapy*; D003840:Deoxycholic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D015725:Fluconazole / Q000627:therapeutic use; D006801:Humans; D007362:Intensive Care Units; D010818:Practice Patterns, Physicians'; D051437:Renal Insufficiency / Q000139:chemically induced
chemical_list: D000935:Antifungal Agents; D004338:Drug Combinations; D003840:Deoxycholic Acid; D000666:Amphotericin B; C059765:amphotericin B, deoxycholate drug combination; D015725:Fluconazole; D003404:Creatinine